DLL4 and pancreatic neoplasm: Two trials evaluating the combinations of gemcitabine (±protein-bound paclitaxel) and anti-DLL4 demcizumab for the treatment of advanced pancreatic cancer have been registered (NCT01189929 and NCT02289898).